Clinical Trial Update: Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Non-randomized Phase 2 trial assessing pain efficacy of Radium-223 in symptomatic metastatic castration-resistant prostate cancer has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Prostate Cancer, Pain | Phase 2 | Status: COMPLETED | Results posted: 2023-04-07